Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010

Sally V. J. Bowskill, M.X Patel, Simon Handley, Robert Flanagan

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)

Abstract

Objective: This study aimed to investigate the effect of dose and other factors on plasma amisulpride concentrations in clinical practice. 

Method: Amisulpride therapeutic drug monitoring data 20022010 have been studied. 

Results: There were 296 samples (196 adult patients). Amisulpride was not detected in 10% of samples. In the remainder, the mean plasma amisulpride in relation to the prescribed dose (mg/day) was as follows: 100200 (111?mu g/L), 201400 (254?mu g/L), 400800 (421?mu g/L), and 8001200 (494?mu g/L). For prescribed doses up to 800?mg/day, only 51% of results were within 100319?mu g/L. There were no significant sex differences in mean plasma amisulpride or mean dose. The mean plasma amisulpride, but not the dose, was significantly higher in smokers. Linear regression analysis showed that dose explained only 42% of the variation in plasma amisulpride after log10 transformation of both variables. There was no significant difference in the mean dose or mean plasma amisulpride in patients co-prescribed clozapine as compared with the remaining samples. 

Conclusion: In practice, dose is a poor predictor of plasma amisulpride concentration. Therapeutic drug monitoring may not only help assess adherence, but also guide dosage.

Original languageEnglish
Pages (from-to)507-513
Number of pages7
JournalHuman Psychopharmacology : Clinical and Experimental
Volume27
Issue number5
DOIs
Publication statusPublished - Sept 2012

Cite this